Biotech and Pharmaceuticals Life Sciences

More

  • Venter on killing cancer

    J. Craig Venter, Human Longevity Inc., CEO, on how science is on the verge of finding cancer in its earliest stages.

  • CNBC Pro: Big business of human longevity

    J. Craig Venter, Human Longevity Inc., CEO, discusses how advances in technology could expand human life spans.

  • July 19- Privately held Jounce Therapeutics Inc, which is working on treatments designed to use a patients' own immune systems to better attack cancer, said on Tuesday it had entered into an collaboration and investment agreement with Celgene Corp worth more than $2.5 billion. The deal for the tiny Cambridge, Massachusetts- based company comes just at little...

  • Aedes aegypti mosquito, the species which transmits the dengue virus, chikungunya fever and zika

    Utah health officials said a caregiver of an elderly patient who died while infected with Zika is positive for the virus.

  • NEW YORK, July 14- Martin Shkreli, the former pharmaceutical executive who last year became a lightning rod for criticism of soaring prescription drug prices, is now scheduled to go on trial in June 2017 in the U.S. government's securities fraud case against him. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against...

  • NEW YORK, July 14- Martin Shkreli, the former pharmaceutical executive who became a lightning rod for criticism of soaring prescription drug prices last year, is now scheduled to go on trial in June 2017 in the U.S. government securities fraud case. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against Shkreli and Evan...

  • NEW YORK, July 14- A federal judge on Thursday scheduled a trial for June 2017 in the U.S. government's securities fraud case against former pharmaceutical executive Martin Shkreli, who became a lightning rod last year for criticism of soaring prescription drug prices. District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case...

  • District Judge Kiyo Matsumoto, in Brooklyn, New York, set a June 26, 2017, trial date in the case against Shkreli and Evan Greebel, a former lawyer for Retrophin Inc, a biopharmaceutical company which Shkreli headed until 2014..

  • July 12- Pfizer Inc said on Tuesday the U.S. Food and Drug Administration had expanded the use of its best-selling pneumonia vaccine, Prevnar, to adults aged 18 through 49.. Prevnar has been buoying Pfizer's revenue, helping the company beat Wall Street estimates. The Prevnar range of products grossed annual sales of $6.25 billion in 2015, up 40 percent from a year...

  • Elizabeth Holmes

    U.S. regulators have banned Elizabeth Holmes, the chief executive of Theranos, from owning or operating a laboratory for at least two years.

  • *Accord with Walter Reed Army Institute of Research. PARIS/ LONDON, July 6- French drugmaker Sanofi said on Wednesday it had struck a research and development deal with the U.S. Army to speed up the development of a vaccine against the mosquito-borne Zika virus. The tie-up with the Walter Reed Army Institute of Research in the United States gives Sanofi access to a...

  • LONDON, June 22- Roche is increasingly confident it will continue to lift sales and profit even as cut-rate copies of the Swiss drugmaker's older cancer medicines start to grab business next year, its chief executive said on Wednesday. Big wins for three new drugs in recent months have helped to offset what Roche's Severin Schwan acknowledges as a serious...

  • June 20- Drug developer Inovio Pharmaceuticals Inc and its partner GeneOne Life Sciences Inc said they had received approval from U.S. regulators to start an early stage human trial testing their Zika vaccine. In February, the World Health Organization declared Zika a global public health emergency. India's Bharat Biotech is another company that is in the...

  • June 20- Drug developer Inovio Pharmaceuticals Inc and its partner GeneOne Life Sciences Inc said they had received approval to start an early stage human trial testing their Zika vaccine. The early-stage study will enroll 40 healthy subjects and evaluate safety, tolerability and immune response generated by the vaccine GLS-5700. "We plan to dose our first...

  • CHICAGO, June 4- Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a patient's tumor rather than the organ in which the cancer was originally detected. The findings, presented at the annual meeting of the American Society of Clinical Oncology in...

  • May 31- Switzerland's AC Immune, which already has money in hand from Roche for its most advanced drug, is planning a share sale in the United States to raise up to $50 million for separate drug candidates targeting Alzheimer's disease. The company, run by former Nestle global research head Andrea Pfeifer, joins other European biotech firms that have opted to list...

  • May 31- StemCells Inc said it would wind down operations after the company terminated a mid-stage trial testing its therapy in spinal cord injury, sending its shares plummeting 85 percent. The Newark, California- based biotech said it had cash and cash equivalents of about $5.5 million as of May 31. "In the end, a combination of the tough market environment and long...

  • Modern medicine's latest tool? Gene editing

    CNBC's Meg Tirrell talks with Dr. Jennifer Doudna, UC Berkeley professor and CRISPR technology pioneer about the scientific breakthrough of editing genes as a possible cure for hundreds of diseases.

  • BRIEF-GSK SAYS GENE THERAPY FOR IMMUNE DISORDER MEETS MAIN. *Key efficacy endpoint for analysis was survival. All 18 patients were alive after a median follow-up of 6.9 years at data cut on 8th may 2014.

  • May 24- France's Sanofi SA is preparing to name candidates it will put forward to replace the entire board of U.S. cancer drug company Medivation Inc as early as Wednesday, according to people familiar with the matter. Medivation shares ended trading on Tuesday in New York at $61.91. Among Sanofi's eight nominees are Michael Campbell, the former chief executive...